Background: Autoactivation of initiator proteases of complement is a two-step process. Results: Autoactivation, and possible crossactivation steps of complement lectin pathway proteases were quantified. Conclusion: Only MASP-1 can autoactivate rapidly, and MASP-2 is activated by MASP-1. Significance: The determined kinetic data are helpful to interpret activation scenarios for the lectin pathway, and the presented strategy can be used to quantify autoactivation of other proteases.
Autoactivation is central to several proteolytic cascade systems, such as the coagulation cascade (1, 2) , the complement system (3) (4) (5) , the system of digestive enzymes (trypsinogen activation) (6) , and the caspase system (7, 8) . "Autocatalytic activation" in these systems is quite common, where an activated protease cleaves its own zymogen form serving a positive feedback for the activation process. There is another possibility that we term "zymogen autoactivation", where one proenzyme molecule cleaves another proenzyme of the same protease. This mechanism is less common (3, 9) . Prominent examples are two pathways of the complement system: the classical and the lectin pathways. In these systems both the zymogen autoactivation and the autocatalytic activation mechanisms play a role. In the contact-kinin cascade fXII autoactivates on certain surfaces, where a similar scenario is possible (10) .
The complement system (11) is composed of a network of serine proteases, recognition and regulatory molecules. Its main role is to eliminate invading microorganisms, and altered self-structures, and in general it contributes to the immune homeostasis of the body. The complement system can be activated via three (interconnected) pathways: the classical, the lectin and the alternative routes. The initiator complex of the classical pathway, C1, is composed of a recognition molecule, C1q, and a C1s-C1r-C1r-C1s protease heterotetramer. Upon binding to activator surfaces C1r autoactivates, presumably in two steps, then it activates the C1s subcomponents, which then cleave the subsequent components of the complement cascade C4 and C2. A similar mechanism occurs in the lectin pathway of complement, however mannan-binding lectin (MBL) 2 -associated serine proteases, MASP-1 and MASP-2, are able to autoactivate separately (12, 13) , at least in vitro. In the lectin pathway the picture is much more complex compared to the classical pathway, since there are five known pattern recognition molecules (MBL, H-, L-, and M-ficolins, and collectin-11), three associated serine proteases (MASP-1, -2, -3), and two other associated proteins (MAp19, and MAp44) (14) (15) (16) (17) (18) .
The major player in lectin pathway activation has been thought to be MASP-2, as it can autoactivate, and cleave both C4 and C2 (12, 13, 19) . However, recent studies have shown that in normal serum MASP-1 activates MASP-2 (20) (21) (22) (23) (24) , and MASP-1 is responsible for 60% of the C2 cleavage (20) . Both MASP-1 and -2 are therefore essential components of the lectin pathway. On the other hand, the exact role of the other associated proteins (MASP-3, MAp19, and MAp44) remains to be clarified (16, 25) . MASP-3 was recently shown to be activated by MASP-1 (24, 26) , and it might be involved in alternative pathway activation (26) .
All MASPs and MAps (MBL-associated proteins) are Ca 2+ -dependent dimers. The Nterminal CUB-EGF-CUB region is responsible for the dimerization of MASPs and their association with MBL and ficolins. At present, the generally accepted model is that MASP and MAp homodimers bind to distinct recognition molecules (16, 27, 28) , however at least some of the MBL or ficolin molecules present in higher oligomeric state can potentially bind multiple dimers (24, 29) .
MASP-1, and -2, as well as C1r circulate in the blood in zymogen (proenzyme) form, hence their autoactivation must take place in two stages. First one proenzyme cleaves another proenzyme (zymogen autoactivation), then the activated enzyme cleaves other proenzyme molecules (autocatalytic activation). In the case of C1r the two autoactivation steps are thought to take place within the same C1 complex (30) . Whether MASPs autoactivate within the same complex, or they activate MASP molecules on neighboring complexes remains to be clarified.
Structure of the catalytic region of active MASP-1 (31) and that of both zymogen and active MASP-2 (9, 32) have been determined. Proenzymic MASP-1 structure has been lacking till now. Both MASP-1 and -2 have potential targets outside the complement system (16, (33) (34) (35) (36) , but in general MASP-1 has a broader substrate specificity, which is reflected in its structure (31) .
Under physiological circumstances MASPs associated with their recognition molecules, and C1r as part of the C1 complex autoactivate, when these complexes bind to activating surfaces. Autoactivation, however, is also observed on isolated C1r (3) and MASPs (27) , and on recombinant fragments as well (9, 13) . Upon activation a specific Arg-Ile bond is cleaved in the serine protease (SP) domain of these enzymes. Changing the Arg to a Gln residue renders the resulting Gln-Ile bond resistant to proteolysis making the enzyme a stable proenzyme (9, (37) (38) (39) . Hence, the autoactivation process can be modeled using recombinant fragments, and a stable zymogen form of these enzymes can be obtained by mutating a specific Arg to Gln. Another mutation is commonly used for serine proteases, where the active site Ser residue is changed to Ala (40) (41) (42) . This mutation results in inactive MASPs having unaltered scissile Arg-Ile bond. These variants serve as zymogen substrates in kinetic measurements of the autoactivation reactions.
Our aim was first to separate the two autoactivation steps of MASP-1 and MASP-2, and quantitatively measure the rate constants of each step for both enzymes using wt and mutant recombinant catalytic fragments. We have also crystallized a stable proenzyme variant of MASP-1 encompassing the CCP1-CCP2-SP domains and solved its structure. Later we extended our studies to the possible cross activation steps, i.e. we measured the rate constants for MASP-2 activation by MASP-1, and vice versa. The biggest difference was observed in the zymogen autoactivation reactions: in this respect MASP-1 is about 3000-times more efficient than MASP-2. The kinetic data suggest that the lectin pathway activation starts with the rapid autoactivation of MASP-1, which then cleaves MASP-2. At the beginning of this study we had no preconceived assumptions regarding the mechanism of lectin pathway activation, however in a parallel study published recently (20) , we have shown using specific inhibitors, that MASP-1 is the exclusive activator of MASP-2 in normal human serum. The conclusions of the two studies are in a perfect agreement further emphasizing the key role of MASP-1 in the initiation of lectin pathway activation.
EXPERIMENTAL PROCEDURES

Recombinant MASPs
DNA constructs of recombinant human MASP-1 and MASP-2 catalytic fragments encoding the CCP1-CCP2-SP region (rMASP) were used for expression in E. coli as described (13) . The R448Q and S646A (precursor numbering) mutants of rMASP-1 were made by mutagenesis using the QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies). The analogous R444Q and S633A mutants of rMASP-2 were made earlier (9, 20) . The plasmid for the expression of recombinant human MASP-3 catalytic fragment (CCP1-CCP2-SP) was prepared using the pET17b vector (Novagen) analogously to the MASP-1 construct (13) . The encoded protein begins with the MASMT vector derived tag followed by the G 298 -R 728 (precursor numbering) segment of MASP-3.
Wild-type (wt) rMASP-1 was produced as described (43) , but in the absence of benzamidine.
The two-step purification procedure was performed in a single day in order to minimize degradation of wt rMASP-1. The R448Q and the S646A variants of rMASP-1 were prepared just like the wt enzyme, however in these cases the procedure yields the proenzymic (one-chain) form.
Preparation of wt rMASP-2 was slightly modified compared to the original protocol (13) . The expressed inclusion bodies were dissolved in 7 M guanidine-hydrochloride, 50 mM DTT, 50 mM Tris, pH=8.0, then diluted into a 0.75 M Arg, 50 mM Tris, 5 mM EDTA, 300 mM NaCl, 6mM glutathione, 3mM oxidized glutathione, pH=9.0 buffer at a final concentration of 100 mg/L for rMASP-2. The refolding mixture was kept at 4 o C for 1-2 weeks. After excessive dialysis and adjustment to pH=6.3 the rMASP-2 was purified by cation exchange chromatography on a Source 30S (GE Healthcare) column in 10 mM MES, 0.5 mM EDTA, pH=6.3 buffer using a 0-500 mM NaCl gradient. The appropriate fractions were further purified by anion exchange chromatography on a Source 30Q (GE Healthcare) column and eluted by 0-200 mM NaCl gradient in 5 mM Tris, 0.5 mM EDTA, pH=8.8 buffer. The R444Q and the S633A variants of rMASP-2 were prepared like the wt enzyme, however again in these cases the procedure yielded the proenzymic (one-chain) form.
Wt rMASP-3 was produced as follows. The expressed inclusion bodies were dissolved in 7 M guanidine-hydrochloride, 50 mM Tris, 25 mM DTT, then diluted into a 1 M Arg, 50 mM Tris, 5 mM EDTA, 3 mM glutathione, 1 mM oxidized glutathione, pH=8.0 refolding buffer at a final concentration of 100 mg/L for rMASP-3 at 0 o C. The refolding mixture was kept at 4 o C for 1-2 weeks. After excessive dialysis against 50 mM NaCl, 10 mM MES pH=5.7 and application to an SP Sepharose High Performance (GE Healthcare) cation exchange column, rMASP-3 was eluted using a 0-300 mM NaCl gradient in 10 mM MES, 0.5 mM EDTA, pH 6.1 buffer. The appropriate fractions were further purified by anion exchange chromatography on a Source 30Q (GE Healthcare) column and eluted by a 0-200 mM NaCl gradient in 20 mM Tris, 0.5 mM EDTA, pH=8.6 buffer. MASP-3 does not autoactivate, but it can be slowly cleaved by contaminating proteases (20, 40) . When performed in a single day the procedure described produced about 98% zymogenic rMASP-3.
MASP cleavage assays
The rMASP variants, in which the catalytic serine was replaced by alanine, served as substrates, i.e. rMASP-1 S646A, and rMASP-2 S633A. The substrate concentration was in the range of 1-50 µM, as required by the experiment. R448Q or wt rMASP-1, and R444Q or wt rMASP-2 served as enzymes for the cleavage assays. Typical enzyme concentrations were about 500-1000 nM for rMASP-1 R448Q, 1-50 nM for wt rMASP-1, 20-50 µM for rMASP-2 R444Q, and 100-500 nM for wt rMASP-2. Typically a substrate to enzyme ratio of >10 was used, except when rMASP-2 R444Q served as the enzyme, which has a very low activity. In this case a 1:1 ratio was used because of the limited solubility of the substrate proteins. All the possible 8 combinations were assayed. Results of the wt rMASP-1 vs. MASP-2 S633A reaction and the wt rMASP-2 vs. MASP-2 S633A reaction were published previously (20) . As a control rMASP-1 S646A, or rMASP-2 S633A was incubated alone to detect any possible background cleavage by contaminating proteases. For the rMASP-1 S646A cleavage reaction by rMASP-2 R444Q no detectable cleavage attributable to the action of rMASP-2 R444Q was observed.
For rMASP-3 cleavage by wt rMASP-1 (100 nM) wt proenzymic rMASP-3 (2 µM) served as a substrate, since MASP-3 is not capable of cleaving its proenzyme even in the active form (40) . As a control rMASP-3 was incubated alone for the same period of time to detect any possible background cleavage by potential contaminating proteases.
The enzyme and substrate were added on ice to the reaction buffer (140 mM NaCl, 50 mM Hepes, 0.1 mM EDTA, pH7.4), mixed, and a sample was taken for the zero time point. The reaction started by placing the mixture to 37 o C. Samples were removed periodically, and heated with equal volume of reducing SDS-PAGE sample buffer to stop the reaction. Samples were then analyzed by SDS-PAGE. The sample loaded per lane contained 1-2 µg substrate. Gels were stained with Coomassie Brilliant Blue G dye, which was followed by densitometry on a Gel Doc 1000 system using the Molecular Analyst software (Bio-Rad). Either the disappearance of the uncleaved substrate, or the appearance of the B-chain (Fig. 1 ) of the product was quantified.
The observed first order rate constant (k obs ) was determined by nonlinear regression using the I S = I B + I o × exp(-k obs × t) equation, or the I P = I B + I ∞ × [1-exp(-k obs × t)] equation, where I S is the intensity of the substrate band, I o is the intensity at the zero time point I B is the background, whereas I P is the intensity of the product band, and I ∞ is the hypothetical intensity at the completion of the reaction (supplementary Table 1 .
Peptide substrate cleavage and inhibition by SGMI-1
R448Q or wt rMASP-1, and R444Q or wt rMASP-2 were assayed in 140 mM NaCl, 50 mM Hepes, 0.1 mM EDTA, pH7.4 buffer at 25 o C using carboxybenzyl-Gly-Arg-thiobenzylester (Z-Gly-Arg-S-Bzl) as a substrate in combination with an excess of 4,4′-dithiodipyridine used as an acessory reagent for detection at 324 nm. At 20 µM or less Z-GlyArg-S-Bzl the catalytic efficiencies (k cat /K M ) for R448Q or wt rMASP-1, and R444Q rMASP-2 were calculated from the Table 2 .
SGMI-1 is a specific, reversible, tight binding inhibitor of MASP-1 with a K I of 6.5 nM for wt rMASP-1 (21). Here we determined the equilibrium inhibitory constant for proenzymic rMASP-1 R448Q in 140 mM NaCl, 50 mM Hepes, 0.1 mM EDTA, pH7.4 buffer at
25
o C using the same substrate as above. K I was calculated according to Kuzmic et al. (44) .
rMASP-1 R448Q crystallization, data collection, structure determination and refinement
Crystals of the stable zymogen rMASP-1 R448Q variant were grown as follows: 1 µl of rMASP-1 R448Q at a concentration of about 9 mg ml -1 in 50 mM NaCl, 5 mM TRIS, 0.5 mM EDTA, pH=8.8 buffer was mixed with 1 µl of reservoir solution that contained 20% (v/v) PEG400 and 0.1 M imidazole pH 7.0, and crystallized by the vapor-diffusion hanging-drop method. The crystals were gradually soaked into reservoir buffer supplemented with 25 and 30% (v/v) PEG400, and flash-cooled in liquid nitrogen. Following in-house screening on the diffractometer of MTA-ELTE Protein Modeling Research Group, X-ray diffraction data from the best diffracting crystal was collected on the beamline ID 14-1 at the European Synchrotron Radiation Facility (ESRF) (wavelength: 0.9334 Å) at 100 K by helical data collection.
The data were processed and scaled to a resolution of 2.5 Å using the programs XDS and XSCALE (45) . The phase problem was solved by molecular replacement with the program MOLREP (46) of the Collaborative Computing Project 4 (47) . Individual domains of the activated MASP-1 structure (PDB id: 3GOV) were used as search models (31) . Model building and refinement were carried out with the programs Coot (48) and Phenix (49), respectively. TLS refinement was carried out for individual domains of the structure. The model was validated using PROCHECK (50), SFCHECK (51) and MolProbity (52) . Data collection and refinement statistics are shown in Table 3 . Coordinates were deposited in the Protein Data Bank (PDB reference id: 4IGD). Analysis of the contact regions was carried out with the CCP4 program and the PISA server (53) . Structural figures were prepared by PyMOL (54) .
RESULTS
Separation of the autoactivation steps of MASP-1 and -2
In order to study the autoactivation process we have used the CCP1-CCP2-SP catalytic fragments of human MASP-1 and -2. These fragments can be produced in high yield and high purity, which was essential for these studies. Domain structure of full length MASPs and the fragments (rMASP) used for this study are illustrated on Fig. 1A . Both wt rMASP-1 and wt rMASP-2 autoactivate during the purification process at room temperature. We note here that over 98% proenzymic wt rMASP-2 can be produced at 4 o C (9), while wt MASP-1 fully autoactivates during dialysis even at 4 o C. Hence while the autoactivation of zymogen MASP-2 could be studied using the proenzymic wt enzyme (9) , this approach is not feasible for MASP-1. Even when the autoactivation reaction can be studied using the wt zymogen form, the observed curve represents the combination of the two types of autoactivation processes running in parallel.
By mutagenesis stable proenzymic rMASP variants were produced, in which the Arg residue in the scissile Arg-Ile bond was replaced by Gln (rMASP-1 R448Q, and rMASP-2 R444Q). These mutants serve to represent the proenzymic (one-chain) form of these enzymes. Mutants of another type were also made, in which the active site Ser residue was replaced by Ala (rMASP-1 S646A, and rMASP-2 S633A). These mutants serve as ideal, pure substrates for both the wt and the proenzymic variant enzymes, since they still possess the scissile Arg-Ile bond, however they are inactive even in the two-chain ("active") conformation.
Using the wt enzymes and the described mutants (Fig. 1B) the two steps of the autoactivation reaction can be examined and quantified separately.
Quantification of the two autoactivation steps of MASP-1
Measurement of the zymogen autoactivation step of MASP-1 was achieved by using the stable zymogen variant rMASP-1 R448Q, which served as the enzyme, and rMASP-1 S646A, which served as the substrate. The purification procedure yielded pure proteins essentially free from contaminating proteases that could have potentially interfered with the assay. Both rMASP-1 variants are stable when incubated alone, indicating that cleavage was due to the zymogen variant when the two variants were mixed ( Fig. 2A-C) . The determined cleavage rate (k obs /[E] T ) was about 450 M -1 s -1 , which is relatively high for a zymogen serine protease. The autocatalytic activation step was modeled by a reaction where wt rMASP-1 served as the enzyme and the S646A variant as the substrate (Fig. 2D) 
Quantification of the zymogen autoactivation step of MASP-2
Analogously to the previous case the zymogen autoactivation step of MASP-2 was modeled by a reaction where the stable zymogen variant (rMASP-2 R444Q) served as the enzyme and rMASP-2 S633A as the substrate. Measuring the kinetic rate constant for this reaction presented a real challenge, as it was too slow to be measured in the usual time-frame of enzymatic reactions. Very high enzyme and substrate concentration (about 50 µM) had to be used and the total incubation time was about 6 days. Data from a typical experiment is presented on Fig. 3 . When the rMASP-2 S633A variant was incubated alone no significant cleavage was detected during the same incubation period (data not shown). The determined rate constant (k obs /[E] T ≈ 0.14 M -1 s -1 ) indicates an extremely slow initial proenzymic phase for MASP-2 autoactivation.
The rate constant for the autocatalytic activation step (k obs /[E] T ≈ 600 M -1 s -1 ) published earlier (20) combined with the newly determined rate constant for the zymogen autoactivation step indicate that although MASP-2 can autoactivate in vitro, it is several orders of magnitude slower than the autoactivation of MASP-1, and MASP-2 probably requires external cleavage especially for the initial generation of active MASP-2 during the lectin pathway activation.
"Cross-activation" between MASP-1 and -2
If zymogen MASP-2 cannot be cleaved efficiently by its own zymogen, what is the enzyme that causes the initial cleavage when all enzymes are present as zymogens? A logical answer is that MASP-1 autoactivates first, then active MASP-1 cleaves zymogen MASP-2. Another possibility is that zymogen MASP-1 cleaves its own zymogen and zymogen MASP-2 simultaneously, then the generated active enzymes take over.
In order to explore all possibilities we have attempted to measure the activation rates for all combinations. The cleavage of rMASP-2 S633A by wt rMASP-1 (k obs /[E] T ≈ 12 000 M -1 s -1 ) has been determined earlier (20) . The reversal of this reaction (Fig. 4A) Interestingly zymogen MASP-1 is quite efficient MASP-2 activator. This reaction was modeled by the cleavage of rMASP-2 S633A by rMASP-1 R448Q (Fig. 4B) , and the determined cleavage rate (k obs
The values determined for the activity of zymogen MASP-1 and MASP-2 imply that for the initial phase of activation, when all enzymes are present as zymogens, the activation of lectin pathway proteases strictly depends on zymogen MASP-1.
A kinetic model of lectin pathway activation
We have summarized all the kinetic data in Table 1 regarding MASP autoactivation and cross-activation. Also, in order to graphically illustrate how these constant relate to each other we have put them into a MASP-1/2 (auto)activation scheme (Fig. 5) . Although the measured rate constants were determined using recombinant fragments, their relative values should be similar to those of the full-length enzymes and enzymes bound to MBL or ficolins. A kinetic model of the activation of the lectin pathway immediately emerges from Fig.  5 , which is discussed later.
Activation of MASP-3 by MASP-1
Following MASP-1, MASP-3 is the second most abundant MASP or MAp (25, 55) . Recent publications regarding the potential role of MASP-3 in the alternative pathway and its possible cleavage by MASP-1 (24, 26) prompted us to quantitatively characterize the latter reaction. In this case wt zymogen rMASP-3 served as a substrate, since MASP-3 does not autoactivate (40) . Data from a typical experiment is presented on Fig. 6 . As a control zymogen wt rMASP-3 was incubated alone for the same period of time, and no activation was observed (data not shown). The observed cleavage rate of rMASP-3 by rMASP-1 (k obs /[E] T ≈ 1200 M -1 s -1 ) is somewhat lower than the active-zymogen cross activation reactions 7 between MASP-1 and MASP-2 (Table 1) , but still reveals an efficient process. This reaction is not included in the lectin pathway activation scheme (Fig. 5) since we did not explore all the combinations for MASP-3 yet, and the subsequent events (i.e. the roles of active MASP-3) are not well established.
Cleavage of small substrates and inhibition of proenzyme MASP-1
Both wt rMASP-1 and wt rMASP-2 are very active on a synthetic thiobenzyl-ester substrate ( Table 2 ). On amide substrates MASP-1 is usually more active than MASP-2 (56). Nevertheless both active enzymes have readily measurable activity. We attempted to measure the activity of the proenzyme variants using the most sensitive substrate available, Z-Gly-Arg-SBzl. Previously it was reported that rMASP-2 R444Q does not cleave this substrate at all (9), but here we could detect a very weak activity at high enzyme concentration. On the other hand, the zymogen variant rMASP-1 (R448Q) had a significant, easily measurable activity towards this substrate (Table 2) .
SGMI-1 is a specific canonical inhibitor developed against active rMASP-1 using phagedisplay (21) . We have measured the equilibrium inhibitory constant for the zymogen variant rMASP-1 R448Q and SGMI-1. The observed value (K I = 5.5 ± 1.4 nM, n=3, ± SD) is practically the same as the one determined for the wt activated enzyme (6.5 nM). This is somewhat surprising, and shows that this inhibitor can be effective at shutting down the lectin pathway at a very early zymogen stage, and implies that proenzyme MASP-1 can easily adopt an active-like conformation.
Structure of the proenzyme form of rMASP-1
We solved the crystal structure of rMASP-1 R448Q consisting of the CCP1-CCP2-SP segment of the enzyme, and refined it to a 2.5 Å resolution ( Table 3 ). The overall structure is shown in Fig. 7A . The relative orientation of the three domains is essentially the same as in the activated structure (PDB id: 3GOV, RMSD of 352 fitted Cα atoms is 0.754 Å), showing the CCP1-CCP2 moiety in a very similar conformation in both structures (the only difference is in the 406-409 region).
The uncleaved serine protease domain shows characteristics typical to zymogens in the chymotrypsin family: the residues of the catalytic triad are in active conformation, but the oxyanion site is distorted and Asp640 (Asp c189 in chymotrypsin numbering) is rotated (Fig. 7B) . The substrate specificity (S1) pocket is blocked sterically and electrostatically by a positively charged residue (Lys675, c222), similarly to that seen in zymogen MASP-2, where Arg630 (c192) covers the S1 site.
Similarly to several other zymogen structures, in the rMASP-1 R448Q structure the Ser667-Trp668 (c214-c215) peptide bond is rotated which results in a segment of loop 2 (residues 669-670) blocking the S2 and partially the S1' substrate binding pockets, thus being in a collapsed conformation in the zymogen enzyme.
It was proposed that in solution such collapsed forms are in dynamic equilibrium with open conformations of both the zymogen and activated enzymes of the chymotrypsin family, moreover this equilibrium can be shifted by interactions with the substrate or other molecules, and even crystal contacts can stabilize either the open or the collapsed forms (57) . In zymogen MASP-1 the loop 2 region contains mainly polar amino-acids (6 out of 10 residues are charged, see Table 4 and Fig 7C) , therefore solvation would favor the flexible transformation between its open and collapsed forms. In contrast, loop 2 of zymogen MASP-2 appears in open form in its crystal structure (PDB id: 1ZJK; Fig 7D) . However, loop 2 in this latter consists overwhelmingly of hydrophobic residues (10 out of 11 residues, Table 4 ) and the open conformation of the loop is stabilized by hydrophobic crystal contacts, suggesting that for MASP-2 solvation does not promote flexible loop 2 transformation, but hydrophobic interactions with macromolecular substrates may play an important role.
Restoring the S1 and oxyanion sites is essential for enzyme activity. It can be realized through either conformational fluctuation between different forms, or it can be induced during substrate binding. In both cases liberating closely packed part of the activation domain is required. A closely packed region is formed by loops D and 1, containing an important hinge point of the activation-cascade, that is c194 in loop 1. In zymogen MASP-2 this residue (Asp632; accessible surface area: 0.60 Å (58) . In zymogen MASP-1 two positively charged residues (Lys591 and Arg596) of loop D reaching close are candidates for that role (Fig. 7) . In contrast, in MASP-2 where c194 Asp is buried, positively charged residues are farther from the ideal interacting position.
In summary, comparison of the zymogen and activated structures suggest that higher basal activity of zymogen MASP-1 compared to zymogen MASP-2 can be explained by looser packing and more polar character of the loop regions of the activation domain in critical position for the inactive to active conformation change (Table 4) , which is indicated by smaller buried surface area of zymogen MASP-1 and higher extent of its collapse during activation, as well as the different neighborhood of the important hinge point c194 residue.
DISCUSSION
Autoactivation is the intrinsic property of the initiator proteases of complement, namely C1r, MASP-1, and MASP-2, however it turned out from this and parallel studies (20, 24 ) that autoactivation of MASP-2 is probably not relevant physiologically. Proenzyme forms of wt full-length C1r and its catalytic region (3, 59) and rMASP-2 (9) were produced earlier and the kinetics of their autoactivation was studied. The observed sigmoid-shaped activation curve is a result of two reactions: [1] zymogen autoactivation, and [2] autocatalytic activation. The two-step autoactivation reaction can be described by the following scheme, where E is the zymogen and E* is the active enzyme:
The autocatalytic activation can be considerably faster than the zymogen autoactivation step, and preparations of a wild-type proenzyme can contain trace amounts of active enzyme, therefore characterization of the zymogen autoactivation step is particularly challenging. Using stable proenzyme variants of rMASP-1, and -2 (R448Q, and R444Q, respectively), and variants, in which the active site Ser was replaced by Ala (S646A, and S633A), this problem has been overcome. For the first time, we have provided quantitative data for the zymogen autoactivation step of a complement protease.
The determined zymogen autoactivation rate of rMASP-1 is about 3000-fold faster than that of rMASP-2. Based on this observation it seems very unlikely that MASP-2 zymogen autoactivation plays a significant role in the initiation of the lectin pathway.
Using the wild-type forms of rMASP-1 and -2, and the S646A, and S633A variants, the autocatalytic activation steps of rMASPs were quantified. Again the autocatalytic activation rate of rMASP-1 was higher, about 140-fold, than that of rMASP-2. Although MASP-2 can autoactivate in vitro, this is so slow that MASP-2 probably requires external cleavage under a physiological scenario, especially for the initial generation of active MASP-2. On the other hand kinetic data suggest that MASP-1 has a propensity to autoactivate very rapidly.
Using the wild-type, the stable zymogen (R448Q, or R444Q), and the inactive forms (S646A, or S633A) of rMASPs the possible cross-activation steps were also quantified. Earlier we have shown that rMASP-2 S633A is cleaved by active rMASP-1 about 20-fold faster than by its own active form (20) . Now we added the missing rate constants, whenever the cleavage was detectable.
Taking into account all the kinetic data of the 2 autoactivation steps for both proteases and also those of the possible cross-activation steps we have set up a kinetic model of lectin pathway activation (Fig. 5) . In the initial phase, where all MASPs are zymogens, the activity of zymogen MASP-1 controls the activation process. The zymogen autoactivation of MASP-1 is considerably fast, but also, proenzyme MASP-1 can potentially activate proenzyme MASP-2. Whether the latter happens under physiological circumstances depends on the exact composition of MBL/ficolin-MASP complexes, and also on the nature of activation, i.e. intramolecular (within the same complex), or intermolecular (between neighboring deposited complexes).
In the later phase of activation, when enough active MASP-1, and potentially some active MASP-2 is generated, the major player in the activation process is still the more efficient MASP-1. Although active MASP-2 can cleave itself slowly, and it can cleave proenzyme MASP-1 at a considerable rate, one must bear in mind that the concentration of MASP-1 is about 25-fold higher than that of MASP-2 (55). The concentration difference is particularly relevant, if the mode of activation is intermolecular, i.e. MASP-1, or -2 in one complex activates MASPs in neighboring complexes. In this scenario, clearly, MASP-1 is the major activator in every phase of the activation process.
If we assume that the activation process is intramolecular and some of the complexes contain both MASP-1 and -2 (24, 29) , then the concentration of MASP-1 and -2 becomes irrelevant for the activation. Nevertheless even in this scenario our model predicts that in the initial phase, still the activity of zymogen MASP-1 controls the activation process. It is important to note that in the case of an intracomplex activation scenario the orientation of the MASP molecules can have a major effect on the effectiveness of the activation process. This and dimerization of MASP-1 and MASP-2 can greatly influence their activation because of the local concentration effect. This study alone does not support either the intramolecular, or the intermolecular (i. e. inter-complex) activation mechanism, however at least for MASP-2 activation an inter-complex activation is more likely, which is discussed later.
Hence there are certain limitations of our proposed kinetic model. The listed rate constants were determined using recombinant CCP1-CCP2-SP fragment, and not the whole dimeric molecules. We believe that the relative values of these constants are similar for the full length molecules and probably molecules incorporated in MBL-MASP and ficolin-MASP complexes, and serve as good starting points for the interpretation of previous and upcoming experimental data. One must also bear in mind that another MASP, namely MASP-3, and two other MAps (MAp19, and MAp44) are also associated with MBL and ficolins. These components may have regulatory functions and modulate the activation process of the lectin pathway. MASP-3 can be particularly important as it has a high concentration, almost half of that of MASP-1, and it was shown to be associated with a developmental disorder, the 3MC syndrome (60, 61) . MASP-3 and MASP-1 were also suggested to be required for factor D activation and therefore for the activity of the alternative pathway in mice (26, 62) , however at least in human serum this scenario seems unlikely (24) . MASP-3 might cleave factor B though (26) , and it was shown to be activated by MASP-1 (24, 26) . Hence, as a last addition we have measured the cleavage rate of rMASP-3 by rMASP-1. We found that rMASP-1 cleaves rMASP-3 at a rate about 10-fold slower than rMASP-2 (S633A). This is still a significant rate, therefore it is likely that MASP-3 can be slowly activated by MASP-1.
The structure of zymogen MASP-1 catalytic fragment (rMASP-1 R448Q) was determined and refined to a 2.5 Å resolution. The structure shows that rMASP-1 R448Q is in a typical zymogen-like conformation in the crystal. In order to gain catalytic activity it must adopt an active-like conformation, at least temporarily. rMASP-1 R448Q has about 1/240 activity on a small synthetic substrate compared to the wild-type enzyme, and the zymogen autoactivation rate of MASP-1 is about 1/190 of the autocatalytic autoactivation rate. The zymogenicity (63) of MASP-1 therefore shows little substrate dependence. Using the conformational selection (fluctuation fit) model this might indicate that zymogen MASP-1 spends roughly 1/200 of its time in an activelike conformation. Interestingly MASP-2 shows much higher variation of zymogenicity depending on the substrate. The activity of zymogen MASP-2 is 1/83000, 1/4300, and 1/8 of the wt active enzyme on a small synthetic substrate, its own zymogen, and C4 (9), respectively. This might indicate that zymogen MASP-2 cannot effectively adopt an active-like conformation without the aid of an appropriate substrate (induced fit). Comparison of the structures of zymogen and activated MASP-1 and MASP-2 supports this hypothesis. In zymogen MASP-1 the hinge point determining the oxyanion site and loop 1 conformation (Asp645, c194) is accessible, suggesting that its rotation is easier, furthermore the highly polar character of the activation domain facilitates hydration and dynamic conformational behavior of the loops of the activation domain. In contrast, in zymogen MASP-2 the c194 aspartate (Asp632) is buried and the activation domain contains several hydrophobic residues suggesting the hydration of these loops is less favorable and enhancing the relative importance of a suitable binding partner.
We have also determined that SGMI-1, a MASP-1 specific inhibitor, which was developed against the activated wt enzyme (21) also effectively blocks the activity of zymogen MASP-1 as well. When this inhibitor was added to human serum containing zymogen MASPs no lectin pathway activity was detected in a C4 deposition assay (20) . Inhibition of zymogen MASP-1 by SGMI-1 explains why there was no by guest on October 5, 2017 http://www.jbc.org/ Downloaded from MASP-2 activation, hence C4 deposition, observed under these circumstances. It is important to mention that zymogen MASP-2 bound to MBL does not cleave C4, only its isolated fragment (9, 19) , so MASP-2 activation is required for C4 cleavage. In mice deficient in MASP-1 and MASP-3 there is a significant reduction of lectin pathway activation (23, 64) , however there is still some residual activity. Studies with a complex reconstituted from recombinant full-length MASP-2 and isolated MBL showed delayed activation of MASP-2 compared to the natural complexes (12) , but still MASP-2 could activate. All these data together suggest that on surfaces, where MBL-MASP-2 complexes bind in close proximity, MASP-2 can still slowly autoactivate, but when the more abundant MBL-MASP-1 complexes are present, then MASP-2 is exclusively activated by MASP-1 very rapidly. Inhibition of both proenzymic and active MASP-1 by SGMI-1 under these circumstances completely prevents activation of MASP-2. In all, a proximityinduced intermolecular (i. e. inter-complex) activation mechanism can reconcile all the previously mentioned experimental data.
Using recombinant mutant enzymes the two autoactivation steps of an appropriate protease can be studied separately. Particularly challenging is to characterize the "zymogen autoactivation" step, where one zymogen protease cleaves another zymogen molecule. This can be achieved by using a stable proenzyme variant, in which the scissile bond is altered to be resistant to proteolysis, and another mutant, in which the active site residue is mutated. These mutations have to be designed so that the folding of the enzyme is unaffected. It is also important to prepare very pure mutant enzymes, because the activity of the zymogen enzyme is usually low, and possible protease contaminants can interfere with the reaction. Measuring the "autocatalytic activation" step is somewhat simpler. It can be studied using the wild-type enzyme and the active site mutant. This concept can theoretically be applied to any class of proteases.
We have used this approach to serine proteases of the complement lectin pathway, MASP-1 and MASP-2. The two autoactivation steps of both enzymes, as well as the possible "cross activation" steps, were quantitatively characterized. Using the rate constant we have outlined a kinetic model of lectin pathway activation. According to this model MASP-1 autoactivates rapidly, while MASP-2 does not, and MASP-2 is activated dominantly by MASP-1, which is in perfect agreement with recent studies (20) (21) (22) . Our model also adds that in the initial phase, when all MASPs are zymogens, the activity of proenzyme MASP-1 is crucial to the activation of the lectin pathway. Our results also strengthen the view that MASP-1 is a prime target for developing drugs to prevent pathological activation of the lectin pathway. The atomic coordinates and structure factors (code 4IGD) have been deposited in the Protein Data Bank.
FIGURE LEGENDS
FIGURE 1. Recombinant fragments and mutants of MASP-1 and -2. A, Domain structure of MASP-1, and -2, and the recombinant fragments (CCP1-CCP2-SP) designated as rMASP-1 and rMASP-1 used for this study. The disulfide bridge joining the "A" and "B" chains of the full-length protein, and the "short" and "B" chains of the recombinant fragments in the active form is indicated. B, Mutations introduced into rMASP-1 and -2 in order to separate and quantitatively characterize their autoactivation steps, as well as the possible cross-activation steps. FIGURE 2. Separation of the two autoactivation steps of MASP-1. A, Cleavage of rMASP-1 S646A by the R448Q variant modeling the "zymogen autoactivation" step. rMASP-1 S646A at 5.5µM was mixed with rMASP-1 R448Q at 550 nM final concentration, and incubated at 37 o C. B, As a control rMASP-1 S646A (5.5µM ) was incubated alone. No cleavage was observed during the incubation period at 37 o C. C, rMASP-1 R448Q at 550 nM was incubated alone. No cleavage was observed during the incubation period at 37 o C. D, Cleavage of rMASP-1 S646A by wt rMASP-1 modeling the "autocatalytic activation" step. rMASP-1 S646A at 1.1 µM was mixed with wt rMASP-1 at 2.2 nM final concentration, and incubated at 37 o C. Samples were taken at the indicated time points and appropriate amounts (0.5-2 µg per lane) were analyzed by SDS-PAGE under reducing conditions. Fitting is presented in the supplement (Fig. S1 ) and the determined activation rate constants (k obs /[E] T ) are listed in Table 1. FIGURE 3. MASP-2 zymogen autoactivation. Cleavage of rMASP-2 S633A by the R444Q variant was used to model the "zymogen autoactivation" step of MASP-2. rMASP-2 S633A at 45 µM was mixed with rMASP-2 R444Q at 45 µM final concentration, and incubated at 37 o C for 139 hours. Samples were taken at the indicated time points and appropriate amounts (about 2 µg total protein per lane) were analyzed by SDS-PAGE under reducing conditions. Fitting is presented in the supplement (Fig. S1 ) and the determined activation rate constant (k obs /[E] T ) is shown in Table 1 . o C for 7 hours. B, Cleavage of rMASP-1 S646A by wt rMASP-2 modeling a possible cross-activation step, where active MASP-2 cleaves zymogen MASP-1. rMASP-1 S646A at 3.2 µM was mixed with wt rMASP-2 at 100 nM final concentration, and incubated at 37 o C for 150 minutes. Samples were taken at the indicated time points and appropriate amounts (about 2 µg total protein per lane) were analyzed by SDS-PAGE under reducing conditions. Fitting is presented in the supplement (Fig. S1 ) and the determined activation rate constants (k obs /[E] T ) are listed in Table 1. FIGURE 5. A kinetic model of lectin pathway activation. This figure graphically illustrates the kinetic rate constant obtained for the "zymogen autoactivation" and "autocatalytic activation" steps for both MASP-1 and MASP-2, as well as those of the possible "cross-activation" steps. Colored arrows point from the enzyme to the substrate. The model suggests that the autoactivation of MASP-1 is rapid, while the autoactivation of MASP-2 is very slow due to the extremely slow "zymogen autoactivation" step. The model also suggests that MASP-2 is activated primarily by MASP-1, and at the initial phase, when all enzymes are zymogens, zymogen MASP-1 plays a pivotal role in initiating the activation process. FIGURE 6. Activation rMASP-3 by rMASP-1. Cleavage of wt zymogen rMASP-3 by wt (active) rMASP-1 modeling a possible cross-activation step. rMASP-3 at 2 µM was mixed with rMASP-1 at 100 nM final concentration, and incubated at 37 o C for 300 minutes. Samples were taken at the indicated time points and appropriate amounts (about 1.5 µg total protein per lane) were analyzed by SDS-PAGE under reducing conditions. Fitting is presented in the supplement (Fig. S1) -1 (catalytic fragment) . A, The structure consists of the CCP1, the CCP2, and the SP domains (cartoon representation, with the N and C termini, the partially disordered activation loop, and the catalytic triad labeled). B, The catalytic triad (S646, H490, D552) is in active conformation, the rotated D645 residue at the starting point of loop 1 is relatively accessible, while loop 2 (W668-K675 region) is in collapsed conformation (stereo representation, with the 2F o -F c electron density map contoured at the 1 σ level). Comparison of loop compositions and conformations of the activation domains are shown for zymogen structures in C (MASP-1) and D (MASP-2). Loops are colored: activation loop, pink; loop D, blue; loop 1, orange; loop 2, green. The catalytic triad, the hinge points of loop 1 (D645/632 in MASP-1/MASP-2) and loop 2 (W668/655), as well as the aspartate determining the primary substrate specificity (D640/627) and the positively charged residue blocking the S1 pocket (K675/R630) are shown with stick. Balls represent further charged residues. Disordered residues are modeled and shown with dots. Loop 1 region of the activated structure is shown for reference (orange, transparent colors) with its positively charged new N-terminus important for reorienting D645/632 as a blue cross. ~83 000 ~83 000 a ±SD, n=3 is indicated b very low activity close to the detection limit 
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